Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA) -l
– 24%mpr, 0%pcr
– Again, a different study showing that neoadj osi alone is not the way to go forward …waiting eagerly for neoadaura.”
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA)
Authors: Jii Bum Lee et al.
